PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Hepatitis B Surface Antigen Screening Among Pregnant Women and Care of Infants of Hepatitis B Surface Antigen-Positive Mothers - Guam, 2014.

Abstract Hepatitis B virus (HBV) infection is endemic among adults in the U.S. territory of Guam (1,2). Perinatal HBV transmission, which occurs at birth from an infected mother to her newborn infant, is a major mode of HBV transmission and maintains HBV endemicity (3). Approximately 90% of HBV-infected infants will develop chronic HBV infection, and approximately 25% of those will die prematurely from liver failure or hepatocellular carcinoma (4,5). Since 1988, the Advisory Committee on Immunization Practices has recommended that all pregnant women be screened for hepatitis B surface antigen (HBsAg), an indicator of HBV infection, and that infants of women who screen positive (HBsAg-positive women) receive postexposure prophylaxis (PEP) (hepatitis B vaccine and hepatitis B immunoglobulin [HBIG]). When received within 12 hours of birth, PEP is 85%-95% effective in preventing perinatal HBV transmission (5,6). Hepatitis B vaccine provides long-term active immunity to HBV infection and HBIG provides short-term passive immunity to HBV infection until the infant responds to the vaccine (5). Hepatitis B vaccine was introduced into the routine universal infant vaccination schedule in Guam in 1988 (1).
PMID
Related Publications

Gaps in the prevention of perinatal transmission of hepatitis B virus between recommendations and routine practices in a highly endemic region: a provincial population-based study in China.

An investigation of perinatal hepatitis B virus infections among a high risk population: the delivery hospital as a safety net.

A study of immunoprophylaxis failure and risk factors of hepatitis B virus mother-to-infant transmission.

Effects of hepatitis B immunization on prevention of mother-to-infant transmission of hepatitis B virus and on the immune response of infants towards hepatitis B vaccine.

Postvaccination serologic testing results for infants aged ≤24 months exposed to hepatitis B virus at birth: United States, 2008-2011.

Authors

Mayor MeshTerms
Keywords
Journal Title mmwr. morbidity and mortality weekly report
Publication Year Start




PMID- 28520708
OWN - NLM
STAT- MEDLINE
DA  - 20170518
DCOM- 20170523
LR  - 20170523
IS  - 1545-861X (Electronic)
IS  - 0149-2195 (Linking)
VI  - 66
IP  - 19
DP  - 2017 May 19
TI  - Hepatitis B Surface Antigen Screening Among Pregnant Women and Care of Infants of
      Hepatitis B Surface Antigen-Positive Mothers - Guam, 2014.
PG  - 506-508
LID - 10.15585/mmwr.mm6619a5 [doi]
AB  - Hepatitis B virus (HBV) infection is endemic among adults in the U.S. territory
      of Guam (1,2). Perinatal HBV transmission, which occurs at birth from an infected
      mother to her newborn infant, is a major mode of HBV transmission and maintains
      HBV endemicity (3). Approximately 90% of HBV-infected infants will develop
      chronic HBV infection, and approximately 25% of those will die prematurely from
      liver failure or hepatocellular carcinoma (4,5). Since 1988, the Advisory
      Committee on Immunization Practices has recommended that all pregnant women be
      screened for hepatitis B surface antigen (HBsAg), an indicator of HBV infection, 
      and that infants of women who screen positive (HBsAg-positive women) receive
      postexposure prophylaxis (PEP) (hepatitis B vaccine and hepatitis B
      immunoglobulin [HBIG]). When received within 12 hours of birth, PEP is 85%-95%
      effective in preventing perinatal HBV transmission (5,6). Hepatitis B vaccine
      provides long-term active immunity to HBV infection and HBIG provides short-term 
      passive immunity to HBV infection until the infant responds to the vaccine (5).
      Hepatitis B vaccine was introduced into the routine universal infant vaccination 
      schedule in Guam in 1988 (1).
FAU - Abara, Winston E
AU  - Abara WE
FAU - Cha, Susan
AU  - Cha S
FAU - Malik, Tasneem
AU  - Malik T
FAU - DeSimone, Mia S
AU  - DeSimone MS
FAU - Schumann, Bernadette
AU  - Schumann B
FAU - Mallada, Esther
AU  - Mallada E
FAU - Klemme, Michael
AU  - Klemme M
FAU - Aguon, Vince
AU  - Aguon V
FAU - Santos, Anne Marie
AU  - Santos AM
FAU - Collier, Melissa
AU  - Collier M
FAU - Kamb, Mary
AU  - Kamb M
LA  - eng
PT  - Journal Article
DEP - 20170519
PL  - United States
TA  - MMWR Morb Mortal Wkly Rep
JT  - MMWR. Morbidity and mortality weekly report
JID - 7802429
RN  - 0 (Hepatitis B Surface Antigens)
RN  - 0 (Hepatitis B Vaccines)
RN  - 0 (Immunoglobulins)
RN  - XII270YC6M (hepatitis B hyperimmune globulin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Female
MH  - Guam/epidemiology
MH  - Hepatitis B/epidemiology/*prevention & control/transmission
MH  - Hepatitis B Surface Antigens/*analysis
MH  - Hepatitis B Vaccines/administration & dosage
MH  - Humans
MH  - Immunization Schedule
MH  - Immunoglobulins/administration & dosage
MH  - Infant
MH  - Infectious Disease Transmission, Vertical/*prevention & control/statistics &
      numerical data
MH  - Mass Screening/*statistics & numerical data
MH  - Maternal-Child Health Services
MH  - Middle Aged
MH  - Post-Exposure Prophylaxis/utilization
MH  - Pregnancy
MH  - Pregnancy Complications, Infectious/*diagnosis/epidemiology
MH  - Young Adult
EDAT- 2017/05/19 06:00
MHDA- 2017/05/24 06:00
CRDT- 2017/05/19 06:00
AID - 10.15585/mmwr.mm6619a5 [doi]
PST - epublish
SO  - MMWR Morb Mortal Wkly Rep. 2017 May 19;66(19):506-508. doi:
      10.15585/mmwr.mm6619a5.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>